NASAL ADMINISTRATION OF DESMOPRESSIN

Abstract: A pharmaceutical composition for single, effective and consistent plasma level, nasal administration comprises an aqueous solution having a volume of from about 5 to about 75 mu l and from about 0.2 to about 2.0 mg/ml of desmopressin acetate, a molarly corresponding amount of desmopressin or a pharmaceutically acceptable salt of desmopressin. The composition is useful for the management of urinary disorders such as diabetes insipidus, incontinence, and nocturnal enuresis.

Description: NASAL ADMINISTRATION OF DESMOPRESSIN FIELD OF THE INVENTION The present invention relates to nasal administration of desmopressin, desmopressin acetate and other pharmaceutically acceptable desmopressin salts, and to optimal compositions for such administration. BACKGROUND OF THE INVENTION Nasal administration is an attractive route for delivery of therapeutic peptides. However, the art is deficient in optimal conditions for intranasal deposition of peptide drugs which have to overcome the nasal mucosal barrier, enter the systemic circulation and be delivered, in effective form, to intended peripheral target organs. In addition, most of the known peptides suitable for nasal administration are expensive, and the current trend is wasteful "over" delivery of such expensive nasal peptides. There is thus a need in the art for improvements in nasal peptidal administration. Dispensing volumes lower than 50 μl by nasal pump is reported as being unacceptable as dose accuracy and probability of effective delivery to target organs is not assured; on the other hand, a higher volume, over 150 μl, is considered in the art as unsuitable as this is known to lead to flooding: F. Moren, Aerosol s in Medi cine . Moren et al . , Eds., page 346, Elsevier Scientific, Amsterdam (1993) . There is a need for accurate delivery and an economical system for effective nasal administration of peptides. In particular, a need exists for an accurate and optimal delivery system for effective nasal administration of desmopressin (hereinafter also "DDAVP) . OBJECTS OF THE INVENTION It is an object of the invention to provide a single dose pharmaceutical composition of desmopressin, desmopressin acetate or other pharmaceutically acceptable desmopressin salts for nasal administration, which composition is an improvement, providing optimal, effective delivery to .peripheral targets. It is another object of the invention to provide an aqueous stock solution of desmopressin, desmopressin acetate or a salt of desmopressin. A further object is to provide a means for nasal administr¬ ation of an aqueous stock solution of desmopressin, desmopressin acetate or other pharmaceutically acceptable desmopressin salts, for repeated and consistent dispensation of a volume of 5 to 75 μl, more preferred a volume from 10 to 50 μl, and in particular a volume of about 20 to 45 μl . Yet another object is to provide a method for nasal administration of desmopressin, desmopressin acetate or other pharmaceutically acceptable desmopressm salt in a convenient manner such that consistent, effective concentrations are delivered to the plasma of a patient. An additional object of the invention is to provide a method for manufacture of a medicament for treating urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis. These and other objects will be apparent to those skilled in this art after having the benefit of this disclosure. SUMMARY OF THE INVENTION For purposes of this description, desmopressin (DDAVP) is 1- (3-mercaptopropιonιc acid) -8-D-argιnιne vasopressin. The term "nasal" comprises the term "intranasal" meaning, in context, the delivery of drugs through the nasal mucosa. The invention includes a single dose pharmaceutical com¬ position for nasal administration comprising an aqueous solution having a volume of from about 5 to about 75 μl, with the solution containing from about 0.1 to about 2.0 mg/ml of a compound selected from desmopressin, desmopressin acetate or a pharmaceutically acceptable salt of desmopressin. The solution can have a volume of from about 10 to about 50 μl; from about 20 to about 45 μl; or about 35 μl. The compound is from about 0.1 to about 0.5 mg/ml or about 0.5 to about 2.0 mg/ml in the solution. Also included in the invention is a means for delivery in conjunction with a nasal spray pump or a device for dropwise nasal administration for repeated dispensation of a volume from about 5 to about 75 μl of an aqueous solution containing from about 0.1 to about 2.0 mg/ml of desmopressin, desmopressin acetate or a pharmaceutically acceptable desmopressin salt. The solution in the delivery means has a volume of from about 10 to about 50 μl; from about 20 to about 45 μl; or about 35 μl . Another aspect of the invention is a method for delivery of consistent plasma levels of nasally administered desmopressin, desmopressin acetate or a pharmaceutically acceptable desmopressin salt, at from about 10 to about 50 μl of an aqueous solution containing desmopressin, desmopressin acetate or a pharmaceutically acceptable desmopressin salt in the range of from about 0.1 to about 2.0 mg/ml in the solution. The method is useful for treating urinary disorders such as diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis. BRIEF DESCRIPTION OF THE DRAWING Fig. 1 depicts the graphical results of research associated with the present invention. DETAILED DESCRIPTION OF THE INVENTION According to the present invention, single doses of pharma¬ ceutical compositions in the form of aqueous solutions having a volume of from 5 to 75 μl and containing from 0.1 to 2.0 mg/ml of desmopressm, desmopressin acetate or a molarly corresponding amount of a pharmaceutically acceptable salt thereof, are provided. The compositions of the present invention are useful for the management of various urinary disorders such as those associated with diabetes insipidus, incontinence and enuresis, in particular, nocturnal enuresis. The aqueous solution preferably has a volume of 10 to 75 μl . More preferred is a volume of from 15 to 50 μl, and in particular, a volume of about 20 to 45 μl . Independent of the preferred volumes for the aqueous solution, it is preferred for the concentration of desmopressm to range from 0.1 to 0.5 mg per ml, or from 0.5 to 2.0 mg per ml . According to the invention, a sealed container specific for use with a nasal spray pump or a device for dropwise nasal administration is provided, for repeated dispensation of a volume of 5 to 75 μl, more preferred a volume from 10 to 50 μl, and, in particular, a volume of about 20 to 45 μl, of an aqueous stock solution of desmopressin, desmopressin acetate or other pharmaceutically acceptable desmopressin salt. The sealed container dispenses single, consistent doses of a stock solution containing from 0.1 to 0.5 mg per ml or from 0.5 to 2.0 mg per ml of desmopressin acetate or a molarly corresponding amount of desmopressm or other suitable, pharmaceutically acceptable salt of desmopressin. The spray pump or the device for dropwise administration may be integrated with the container and be disposable. The spray pump is preferably of the precompression type and designed for delivery of a volume within the range of from 5 to 75 μl. The single dose composition and the stock solution according to the invention may contain osmotic-pressure controlling agents such as sodium chloride; preservatives such as chlorbutanol or benzalkonium chloride; a buffering agent such as sodium phosphate or sodium citrate buffers designed to maintain a pH from about 4 to about 6, preferably of about 5; and absorption enhancing agents such as bile salts, monolauryl ethers of macrogols and fusidate derivatives . Other pharmaceutically acceptable solutions and compositions in sealed containers for use with a spray pump or a device for dropwise nasal administration for dispensation of a single dose of a pharmaceutical composition of desmopressm, desmopressin acetate or other pharmaceutically acceptable desmopressin salts in molar ranges equivalent to those herein described are well within the scope of this disclosure. Also disclosed is the manufacture of a medicament for treating urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis, the medicament comprising a compound selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable desmopressin salt, the medicament comprising from about 10 to about 75 μl of an aqueous solution containing said compound in the range of from about 0.1 to about 2.0 mg/ml of said solution. The invention is based on the finding that intranasal administration of desmopressin acetate at a concentration of about 1.5 μg/μl gives rise to essentially the same desmopressin concentration profile in plasma independent of the amount administered over a range from 25 to 100 μl for adults and is equally effective as such a range of administration. This pattern extends to even lower volumes for adults, such as a volume of 10 to 15 μl, and for children, to a volume below 10 μl, such as a volume of about 5 to 7 μl . Presently available metering spray pumps on the market are not useful for reproducible dispensation of volumes below about 50 μl. This is due to lack of incentive for developing and marketing such pumps because the volume/concentration/desmopressin plasma level relationship according to the invention is being disclosed uniquely for the first time by this description. The following example demonstrates the independence of the effect of plasma desmopressin from the administered volume of a desmopressin solution of given desmopressin acetate concentrations. EXAMPLE A stock solution containing 0.3 mg desmopressin acetate per ml in distilled water was prepared. Varying doses of this stock solution were administered to six healthy male volunteers. Administration was in the form of nasal spray by using metered spray pumps provided with nebulizer heads. The following dosages were administered to each nostril of each human volunteer: 75 μg in 25 μl, 150 μg in 50 μl, 210 μg in 70 μl, and 300 μg in 100 μl . The combined results are summarized by the graph depicted in Fig. 1. Whereas individual variations were present in the desmopressin plasma profile, the dose volume/plasma profile relationship was essentially the same for all tested individuals . Fig. 1 shows that, within the dosage range investigated, the plasma level effect is not dependent on the administered volume of a desmopressin solution of a given desmopressin acetate concen¬ tration (1.5 μg/μl) . This relationship also holds for a broader range of concentrations, such as from 0.1 μg/μl to 2 μg/μl, and for desmopressin and pharmaceutically acceptable salts of desmopressin other than the acetate . Various modifications and alterations to the present inven¬ tion may be appreciated based on a review of this disclosure. These changes and additions are intended to be within the scope and spirit of this invention as defined by the following claims.

Claims: C l a i m s 1. A single dose pharmaceutical composition for nasal administration comprising: an aqueous solution having a volume of from about 5 to about 75 μl; and said solution containing from about 0.1 to about 2.0 mg/ml of a compound selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable salt of desmopressin. 2. The composition of claim 1, wherein said solution has a volume of from about 10 to about 50 μl . 3. The composition of claim 1, wherein said solution has a volume of from about 20 to about 45 μl. 4. The composition of claim 1, wherein said solution has a volume of about 3b μl . 5. The composition of claim 1, wherein said compound is from about 0.1 to about 0.5 mg/ml in said solution. 6. The composition of claim 1, wherein said compound is from about 0.5 to about 2.0 mg/ml m said solution. 7. A means for delivery in conjunction with a nasal spray pump or a device for dropwise nasal administration for repeated dispensation of a volume from about 5 to about 75 1 of an aqueous solution containing from about 0.1 to about 2.0 mg/ml of desmopressin, desmopressin acetate or a pharmaceutically acceptable desmopressm salt. 8. The means of claim 7, wherein said solution has a volume of from about 10 to about 50 μl. 9. The means of claim 7, wherein said solution has a volume of from about 20 to about 45 μl . 10. The means of claim 7, wherein said solution has a volume of about 35 μl . 11. A method for delivery of consistent plasma levels of a peptide compound, comprising nasal administration of said compound which is selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable desmopressin salt, at from about 10 to about 75 μl of an aqueous solution containing said compound m the range of from about 0.1 to about 2.0 mg/ml of said solution. 12. The method of claim ll, wherein said volume is in the range of from about 10 to about 50 μl . 13. The method of claim 11, wherein said volume is in the range of from about 20 to about 45 μl . 14. The method of claim 11 for treating urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis. 15. The manufacture of a medicament for treating urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis, the medicament comprising a compound selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable desmopressm salt, the medicament comprising from about 10 to about 75 μl of an aqueous solution containing said compound in the range of from about 0.1 to about 2.0 mg/ml of said solution.

Inventors: BENGTSSON BENGT, BENGTSSON, BENGT
Applicants: FERRING AB, FERRING BV, FERRING B.V.
Application year: 1997
Main classification: A61K9
IPC codes: A61K9, A61K31, A61K38, A61M15, A61P5, A61P13